
    
      Study design:

      This study is a prospective, randomized, open-label, multicenter phase II trial in order to
      determine progression-free survival of patients with refractory or relapsed metastatic
      uterine leiomyosarcomas or other metastatic uterine tumours.

      Indication:

      Relapsed or metastatic uterine leiomyosarcomas or carcinosarcomas

      Randomization:

      Patients with uterine leiomyosarcomas will be randomized in a 1:1-fashion to receive the
      following therapy

        -  Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d
           1 and d 8 q3w or

        -  Arm B: Pazopanib 800 mg orally once daily Patients with uterine carcinosarcomas will be
           treated according to Arm A.

      Planned number of patients:

      87 patients with uterine leiomyosarcomas 20 patients with uterine carcinosarcomas

      Treatment schedules:

      Patients with uterine leiomyosarcomas will be randomized in a 1:1-fashion to receive the
      following therapy • Arm A (experimental arm / combination arm): Pazopanib 800 mg orally once
      daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or

      • Arm B (control arm / monotherapy arm): Pazopanib 800 mg orally once daily Patients with
      uterine carcinosarcomas will be treated according to Arm A.

      Planned treatment duration per subject:

      Patients continue on study treatment until disease progression, death, unacceptable toxicity
      or withdrawal of consent for any reason.
    
  